The FDA granted priority review of the biologics license application for NT-501 as a treatment for macular telangiectasia type 2, according to a press release from Neurotech Pharmaceuticals.
The application for the investigational encapsulated cell therapy has been given a PDUFA goal date of Dec. 17.
The ocular implant is designed to deliver sustained therapeutic doses of ciliary neurotrophic factor to the retina. Healio previously reported that it demonstrated statistically significant results for slowing the progression of macular telangiectasia in two phase 3 registration studies.
“This